The National Immunisation Advisory Committee (NIAC) recommended the move following reports of serious blood clotting events in adults in Norway.
In a tweet, the Irish Minister for Health Stephen Donnelly said it was a "precautionary step".
The World Health Organisation has said there was no link between the jab and an increased risk of developing a clot.
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) said it was aware of the suspension in Ireland and was "closely reviewing reports".
"But given the large number of doses administered, and the frequency at which blood clots can occur naturally, the evidence available does not suggest the vaccine is the cause," a spokesperson said.
The Department of Health in Northern Ireland said it would continue with its vaccine programme after taking guidance from the MHRA.
On Friday, the World Health Organisation said countries should not stop using the vaccine over fears it causes blood clots as there is no indication this is true.
More than 110,000 doses of the AstraZeneca vaccine have been administered in Ireland, which is about 20% of all doses given to date.
In a statement to RTÉ, AstraZeneca said that an analysis of safety data covering more than 17 million doses of the vaccine administered has shown no evidence of an increased risk of the conditions concerned, and that no trends or patterns were observed in clinical trials.
"In fact, the reported numbers of these types of events for Covid-19 Vaccine AstraZeneca are not greater than the number that would have occurred naturally in the unvaccinated population," said a spokesperson.
"A careful review of all available safety data including these events is ongoing and AstraZeneca is committed to sharing information without delay."